3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma NPCE

Neuropace, Inc.

NPCE NASDAQ Biotech & Pharma

Stock factsheet

TickerNPCE
ExchangeNASDAQ
ISIN
WKN
SectorBiotech & Pharma
Size class Small Cap
Market capitalisation 439 Mio. USD As of 2026-08-03

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

Neuropace develops implantable neurostimulation devices for the treatment of drug-resistant epilepsy. The lead product, the RNS System, detects abnormal brain activity and responds in real time with electrical impulses. The company markets its devices to specialist epilepsy centres in the United States.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
Neuropace, Inc.NPCE NASDAQ439 Mio. USD
K-Bro Linen Inc. KBLTSX 439 Mio. USD
Sagimet Biosciences Inc. Series A SGMTNASDAQ 439 Mio. USD
Cabaletta Bio, Inc. CABANASDAQ 437 Mio. USD
Kyverna Therapeutics, Inc. KYTXNASDAQ 444 Mio. USD
Pacific Biosciences of California, Inc. PACBNASDAQ 435 Mio. USD
Tilray Brands Inc. TLRYTSX 434 Mio. USD

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.